MultiVu Video Feed: FDA Approves Reclast(R) the First and Only Single-Dose Treatment Regimen for Paget’s Disease of the Bone

NEW YORK, April 17 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has approved Reclast(R) (zoledronic acid) injection for the treatment of Paget’s disease of the bone, the second most prevalent bone disease after osteoporosis. Reclast is the first and only single-dose treatment regimen for Paget’s disease and the first new treatment for the disease in nearly a decade.

Until today, standard therapies for Paget’s disease — bisphosphonates taken in pill form — had to be taken daily for up to six months. Reclast is given as a single 15-minute intravenous infusion by a healthcare professional.

Studies show that Reclast is more effective, offers a longer period of remission and starts working faster than the current standard treatment, Actonel(R) (risedronate sodium). Reclast works by attaching to bone, stopping excessive bone breakdown and rebalancing the body’s natural bone remodeling process. The FDA is currently reviewing Reclast as a potential once-yearly treatment for postmenopausal osteoporosis.

For more information about Paget’s disease, please contact The Paget Foundation at http://www.paget.org/ or call 800-23-PAGET (800-237-2438).

                              SATELLITE FEEDS:    Tuesday, April 17th, 2007      Tuesday, April 17th, 2007   10:30 AM – 10:45 AM ET         1:30 PM – 1:45 PM ET   G 26                           G 26   Transponder 24                 Transponder 11   C-Band                         C-Band   Downlink: 4180 Horizontal      Downlink: 3920 Vertical    Wednesday, April 18th, 2007   1:30 PM – 1:45 PM ET   G 26   Transponder 11   C-Band   Downlink: 3920 Vertical              Preview and access this video on Pathfire DMG: 21208     Search within the PR Newswire or MultiVu section by story ID # 21208                               or by headline    For technical assistance call Pathfire Customer Care at 1-888-345-0489                       or e-mail support@pathfire.com     NEWS: Only Single-Dose Treatment For Paget’s Disease Receives FDA Approval    FORMAT:  B-Roll   

ADDITIONAL RESOURCES: Video, contact information and more available at http://www.prnewswire.com/broadcast/21208/consumer.shtml

   SOUNDBITES:    — Charlene Waldman, Executive Director, The Paget Foundation     — Frederick R. Singer, M.D., Director, Endocrine Bone Disease Program,       John Wayne Cancer Institute     — Joseph R. Tucci, M.D., Director, Division of Endocrinology and       Metabolism, Roger Williams Medical Center     — Earl Randall, Person living with Paget’s Disease   

B-ROLL INCLUDES: *** Physician-patient consultation** Physician examining X-ray** Patient receiving infusion of Reclast**Patient lifestyle footage** Reclast manufacturing ***

VIDEO PROVIDED BY: Novartis Pharmaceuticals Corporation

FOR TECHNICAL INFORMATION OR HARD COPY, PLEASE CALL: MultiVu Media Relations, 800-653-5313 EXT. 3

Video: http://www.prnewswire.com/broadcast/21208/consumer.shtml

Novartis Pharmaceuticals Corporation

CONTACT: MultiVu Media Relations, 800-653-5313 EXT. 3

Web site: http://www.multivu.com/http://www.paget.org/